Who is sponsoring SIC?

SIC is sponsored by Assistance Publique - Hôpitaux de Paris.

What condition does SIC study?

SIC studies Rheumatoid Arthritis, Spondyloarthritis, Crohn's Disease, Uveitis.

What drugs are being tested in SIC?

Interventions: Switch from REMICADE® to INFLECTRA®.

Last reviewed 2026-01-14 · How we verify

Evaluation of the Switch From the Original Infliximab ( REMICADE®) to Its Biosimilar (INFLECTRA®) in Daily Practice at Cochin Hospital (SIC)

NCT02998398 COMPLETED

The purpose of this study is to evaluate the effectiveness of the switch from the original infliximab ( REMICADE®) to its biosimilar (INFLECTRA®) in all the patients at Cochin hospital receiving REMICADE® for either a rheumatic, gastro-enterologic or ophthalmic condition

Details

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	COMPLETED
Enrolment	262
Start date	2015-10
Completion	2016-06-29

Conditions

Rheumatoid Arthritis
Spondyloarthritis
Crohn's Disease
Uveitis

Interventions

Switch from REMICADE® to INFLECTRA®

Primary outcomes

Percentage of patients continuing INFLECTRA® — after the third infusion of INFLECTRA®, up to 24 weeks
Evaluation of the percentage of patients continuing INFLECTRA® after its third infusion

Countries

France